Table S1.
Mean probabilistic sensitivity analysis results
| Outcome: relapses avoided per patient
| ||||
|---|---|---|---|---|
| Total annual cost per patient (medical + pharmacy costs) | Relapses avoided per patient | Net monetary benefit | Rank | |
| Brexpiprazole | $20,457 | 0.707 | $50,283 | 1 |
| Cariprazine | $22,254 | 0.683 | $46,021 | 2 |
| Lurasidone | $25,457 | 0.623 | $36,814 | 3 |
|
| ||||
|
Outcome: relapse-related hospitalization avoided per patient
| ||||
| Total annual cost per patient (medical + pharmacy costs) | Relapse-related hospitalization avoided per patient | Net monetary benefit | Rank | |
|
| ||||
| Brexpiprazole | $18,940 | 0.719 | $52,978 | 1 |
| Cariprazine | $21,200 | 0.683 | $47,143 | 2 |
| Lurasidone | $23,929 | 0.536 | $29,663 | 3 |
|
| ||||
|
Outcome: QALYs per patient
| ||||
| Total annual cost per patient (medical + pharmacy costs) | QALYs per patient | Net monetary benefit | Rank | |
|
| ||||
| Brexpiprazole | $20,504 | 0.706 | $50,146 | 1 |
| Cariprazine | $22,311 | 0.683 | $45,894 | 2 |
| Lurasidone | $25,549 | 0.623 | $36,706 | 3 |
Abbreviation: QALY, quality-adjusted life-year.